Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy. | Biomolecules | 2025 | 40001507 | PubTator, text mining | PubMed |
| Replacing a Cereblon Ligand by a DDB1 and CUL4 Associated Factor 11 (DCAF11) Recruiter Converts a Selective Histone Deacetylase 6 PROTAC into a Pan-Degrader. | ChemMedChem | 2025 | 39973224 | PubTator, text mining | PubMed |
| Cullin-RING ligase BioE3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous Cereblon ubiquitome. | Cell Commun Signal | 2025 | 39972349 | PubTator, text mining | PubMed |
| MEGA PROTAC, MEGA DOCK-based PROTAC mediated ternary complex formation pipeline with sequential filtering and rank aggregation. | Sci Rep | 2025 | 39953061 | PubTator, text mining | PubMed |
| Workflow for E3 Ligase Ligand Validation for PROTAC Development. | ACS Chem Biol | 2025 | 39932098 | PubTator, text mining | PubMed |
| CRBN deletion enhances mitochondrial metabolism by stimulating mitochondrial calcium accumulation in non-small cell lung cancer. | Life Sci | 2025 | 39914588 | PubTator, text mining | PubMed |
| The histone demethylase KDM5C enhances the sensitivity of acute myeloid leukemia cells to lenalidomide by stabilizing cereblon. | Cell Mol Biol Lett | 2025 | 39881283 | PubTator, text mining | PubMed |
| Development of Potent and Selective CK1α Molecular Glue Degraders. | J Med Chem | 2025 | 39873536 | PubTator, text mining | PubMed |
| Implications of frequent hitter E3 ligases in targeted protein degradation screens. | Nat Chem Biol | 2025 | 39870762 | PubTator, text mining | PubMed |
| A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide. | J Pharm Sci | 2025 | 39870177 | PubTator, text mining | PubMed |
| Development of a versatile system for evaluating the target protein degradation activity of novel ubiquitin ligases utilizing existing PROTACs. | Biochem Biophys Res Commun | 2025 | 39864384 | PubTator, text mining | PubMed |
| Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple Myeloma. | Hemasphere | 2025 | 39850647 | PubTator, text mining | PubMed |
| Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma. | Blood | 2025 | 39841463 | PubTator, text mining | PubMed |
| Lung-specific CRBN knockout attenuates influenza a virus-induced acute lung injury in mice: a potential therapeutic approach. | BMC Infect Dis | 2025 | 39833740 | PubTator, text mining | PubMed |
| Identification of MORF4L1 as an endogenous substrate of CRBN and its potential role as a therapeutic target in cancer. | Sci Rep | 2025 | 39827217 | PubTator, text mining | PubMed |
| Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. | Chem Rev | 2025 | 39818743 | PubTator, text mining | PubMed |
| Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs. | ACS Pharmacol Transl Sci | 2025 | 39816802 | PubTator, text mining | PubMed |
| Development of a Buchwald-Hartwig Amination for an Accelerated Library Synthesis of Cereblon Binders. | ACS Med Chem Lett | 2025 | 39811117 | PubTator, text mining | PubMed |
| Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders. | J Med Chem | 2025 | 39804678 | PubTator, text mining | PubMed |
| Genesis and regulation of C-terminal cyclic imides from protein damage. | Proc Natl Acad Sci U S A | 2025 | 39793072 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=16